Your browser doesn't support javascript.
loading
AI-driven Discovery of Morphomolecular Signatures in Toxicology.
Jaume, Guillaume; Peeters, Thomas; Song, Andrew H; Pettit, Rowland; Williamson, Drew F K; Oldenburg, Lukas; Vaidya, Anurag; de Brot, Simone; Chen, Richard J; Thiran, Jean-Philippe; Le, Long Phi; Gerber, Georg; Mahmood, Faisal.
Afiliação
  • Jaume G; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Peeters T; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Song AH; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.
  • Pettit R; Cancer Data Science Program, Dana-Farber Cancer Institute, Boston, MA.
  • Williamson DFK; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Oldenburg L; Signal Processing Laboratory, EPFL, Lausanne, Switzerland.
  • Vaidya A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • de Brot S; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Chen RJ; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.
  • Thiran JP; Cancer Data Science Program, Dana-Farber Cancer Institute, Boston, MA.
  • Le LP; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Gerber G; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Mahmood F; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
bioRxiv ; 2024 Jul 23.
Article em En | MEDLINE | ID: mdl-39091765
ABSTRACT
Early identification of drug toxicity is essential yet challenging in drug development. At the preclinical stage, toxicity is assessed with histopathological examination of tissue sections from animal models to detect morphological lesions. To complement this analysis, toxicogenomics is increasingly employed to understand the mechanism of action of the compound and ultimately identify lesion-specific safety biomarkers for which in vitro assays can be designed. However, existing works that aim to identify morphological correlates of expression changes rely on qualitative or semi-quantitative morphological characterization and remain limited in scale or morphological diversity. Artificial intelligence (AI) offers a promising approach for quantitatively modeling this relationship at an unprecedented scale. Here, we introduce GEESE, an AI model designed to impute morphomolecular signatures in toxicology data. Our model was trained to predict 1,536 gene targets on a cohort of 8,231 hematoxylin and eosin-stained liver sections from Rattus norvegicus across 127 preclinical toxicity studies. The model, evaluated on 2,002 tissue sections from 29 held-out studies, can yield pseudo-spatially resolved gene expression maps, which we correlate with six key drug-induced liver injuries (DILI). From the resulting 25 million lesion-expression pairs, we established quantitative relations between up and downregulated genes and lesions. Validation of these signatures against toxicogenomic databases, pathway enrichment analyses, and human hepatocyte cell lines asserted their relevance. Overall, our study introduces new methods for characterizing toxicity at an unprecedented scale and granularity, paving the way for AI-driven discovery of toxicity biomarkers.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article